Voyager Therapeutics (VYGR) Misses Q4 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Voyager Therapeutics (VYGR) Misses Q4 EPS by 11c

Voyager Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Highlights

March 15, 2017 7:05 AM EDT

Lead program VY-AADC01 for advanced Parkinsons disease on track to report 6-month data from Cohort 3 and longer-term data from Cohorts 1 and 2 in mid-year 2017

VY-AADC01 Phase 1b data accepted as emerging (late-breaking) oral presentation at the upcoming American Academy of Neurology (AAN) meeting

Three investigational new drug (IND) applications planned within the next 24 months for gene therapy pipeline programs targeting devastating CNS diseases

CAMBRIDGE, Mass., March 15, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company... More